Ciral

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciral

Property Description
Active ingredient Escitalopram Oxalate
Form Oral tablets, oral solution, or liquid drops
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General use Supporting emotional stability and mood regulation
Origin Synthetic, single-isomer compound

Ciral is a prescription-only medication whose active ingredient, Escitalopram, is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). This places it among the antidepressant agents used to support mood and emotional balance. Ciral is a psychoanaleptic agent, with the general purpose of helping the central nervous system restore the chemical stability essential for mental well-being, such as in cases involving persistent anxiety. Escitalopram has an established role as a selective inhibitor of serotonin uptake, which is the basis for its targeted mechanism within the serotonergic system and its regulatory effect on mood.


Escitalopram: A Single-Isomer, Synthetic Compound

The core component in Ciral is Escitalopram Oxalate, a synthetic compound designed as a single-ingredient product. Escitalopram is chemically defined as the pure S-enantiomer (single isomer) of Citalopram. This purification focuses the pharmacological activity, ensuring the specific active component is present, which distinguishes Escitalopram from its predecessor, Citalopram, a racemic mixture. The medication is available for oral administration in forms such as tablets and an oral solution.


How Does Ciral Generally Affect Serotonin Levels?

Ciral's core function is the highly targeted inhibition of Serotonin Reuptake, which supports enhanced serotonergic activity in the brain. The medication acts by binding to the Serotonin Transporter (SERT), preventing nerve cells from rapidly reabsorbing the neurotransmitter serotonin once it is released into the synaptic space. This action increases the availability of serotonin between neurons, which is the foundational general effect Ciral provides for the regulation of emotional processing. This specific, highly selective profile is the primary characteristic of the medication's mechanism in supporting emotional well-being.

What side effects are possible with Ciral?

Possible Side Effects and Safety Information

Ciral (Escitalopram) is associated with officially documented adverse reactions that are categorized by both frequency and the body system affected, as outlined in government regulatory labeling.

Adverse Reaction Classification

Classification Examples of Reactions Systems Affected (SOC)
Very Common (ge 1/10) Headache, Nausea Nervous System, Gastrointestinal
Common (ge 1/100 to <1/10) Insomnia, Somnolence, Increased Sweating, Fatigue, Decreased Libido, Ejaculation Disorder Psychiatric, Reproductive, General Disorders

Serious Adverse Reactions

The label documents the potential for Serotonin Syndrome, a serious nervous system reaction. Cardiac risks include QT-prolongation, which may lead to Torsade de Pointes. The risk of suicidal thoughts and behaviors is noted, particularly in adolescents and young adults, and during the initial months of therapy or following dose adjustments. Other documented serious effects include Seizures, Hyponatremia (low blood sodium levels), and an increased risk of Abnormal Bleeding.

Population-Specific Safety and Constraints

Regulatory documents stipulate caution and dose adjustments for certain populations. The recommended maximum dose for older adults (over 65) and patients with hepatic impairment is 10 mg once daily. The medicine is contraindicated in patients with known QT-interval prolongation and in combination with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of serious adverse reactions like Serotonin Syndrome. Discontinuation symptoms are possible upon cessation, which necessitates a gradual dose reduction.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Ciral (Escitalopram) is defined in official regulatory documents as a medical emergency requiring immediate attention. The officially documented profile is structured around central nervous system (CNS) and cardiovascular effects.

Documented Overdose Presentations

Clinical manifestations listed in regulatory labeling include CNS effects such as dizziness, somnolence, confusion, agitation, seizures, and coma. Gastrointestinal distress, particularly nausea and vomiting, is also documented. Cardiovascular signs frequently involve changes to the heart rate and observed QT interval prolongation on an electrocardiogram (ECG).

Serious Manifestations and Urgent Action

Overdose carries the risk of severe, potentially life-threatening outcomes, including Serotonin Syndrome and serious ventricular arrhythmia, such as Torsade de Pointes (TdP). Due to this risk, official labeling mandates seeking immediate medical attention. If a person has collapsed, experienced a seizure, or cannot be awakened, emergency services must be contacted immediately.

Management and Regulatory Context

Management is strictly symptomatic and supportive because regulatory information confirms that no specific antidote is known for Escitalopram overdose. Treatment focuses on establishing an airway, continuous cardiac and vital signs monitoring, and considering measures like gastric lavage or activated charcoal. Fatal cases are rare with Escitalopram alone and frequently involve concomitant overdoses of other drugs.

Therapeutic Uses of Ciral

Ciral is a prescription medication utilized in the management of bacterial infections across several systems of the body. Its use is indicated for various conditions, including infections of the respiratory tract, such as certain types of pneumonia and bronchitis; the urinary tract; and those affecting the skin and soft tissues. A healthcare provider may also prescribe this agent for certain bone and joint infections, as well as specific gastrointestinal infections, like infectious diarrhea. The purpose of the medication is to aid the body in addressing the underlying bacterial strain, which can help lead to symptomatic relief and resolution of the infection.

Quick Fact: Relief for Bacterial Infections

Regulatory References

  1. NIH MedlinePlus Ciprofloxacin guidance

Eligibility and Restrictions for Use

Ciral is a prescription medicine whose population eligibility is strictly defined by government regulatory documents. The official label establishes distinct categories for use: contraindicated, allowed, and restricted.

Populations Who Must Not Use Ciral (Contraindications)

Ciral is contraindicated and must not be used by patients with a known hypersensitivity to escitalopram or any of its components. Use is strictly prohibited for individuals with known QT interval prolongation or congenital long QT syndrome. Additionally, the medicine is contraindicated if a patient is currently taking a Monoamine Oxidase Inhibitor (MAOI), including Linezolid or intravenous Methylene Blue, or the antipsychotic drug Pimozide.

Age-Group and Condition-Specific Eligibility

Population Regulatory Eligibility Status
Adults (≥18 years) Allowed under standard labeled conditions.
Adolescents/Children Allowed for MDD in those 12 years and older, and for GAD in those 7 years and older (US Label).
Severe Impairment Use with caution in severe renal and hepatic impairment.
Pregnancy/Lactation Restricted; use in pregnancy only if benefit justifies risk. Caution is advised during lactation.
Use Not Established Safety and effectiveness have not been established in children less than 7 years of age.

The label also requires caution in patients with a history of seizures, mania, or certain uncompensated cardiac conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ciral details how co-administration with specific medications, substances, or product classes can alter its concentration in the body or the concentration of the co-administered agent. These interactions are categorized based on their mechanism and clinical significance, including combinations that are contraindicated and those requiring caution with monitoring.

Interacting Product Category Mechanism and Implication Management Constraint
Strong CYP3A4 Enzyme Inhibitors Significantly increases Ciral's systemic exposure by reducing its breakdown. Contraindicated (Do Not Use) for potent inhibitors explicitly listed in the label.
Strong CYP3A4 Enzyme Inducers Significantly decreases Ciral's systemic exposure by increasing its breakdown. Avoid co-administration; may result in loss of Ciral's expected effectiveness.
Gastrointestinal pH Modifiers Alters Ciral's absorption due to changes in stomach acidity. Requirement for time separation between administration of Ciral and certain acid-reducing agents, as specified in the official documents.

Interactions involving certain P-glycoprotein transporter inhibitors may necessitate careful patient monitoring, as systemic exposure of Ciral can be affected. Furthermore, Ciral is documented in official labeling to have the potential to interfere with certain laboratory diagnostic assays, which could lead to inaccurate test results. Healthcare providers must follow the procedural constraints defined in the regulatory documents when ordering these specific tests to ensure reliable clinical data.

Mechanism of Action

Ciral's primary mechanism involves the selective inhibition of the Serotonin Transporter (SERT). This action is achieved via binding at the primary orthosteric site (S1) of the transporter, which prevents the rapid reabsorption of the neurotransmitter Serotonin (5-HT) from the synaptic cleft. This blockade results in an elevated extracellular concentration of Serotonin. Its unique mechanism includes binding to the secondary allosteric site (S2), which enhances the inhibitory effect at S1 and contributes to the SERT selectivity of the drug's action within the central Serotonergic system.

Although the SERT blockade is immediate, the long-term functional consequence is dependent on a slower process of neuroplastic adaptation requiring several weeks. This chronic exposure leads to the desensitization and downregulation of inhibitory presynaptic 5 HT1A autoreceptors, which initially limit Serotonin release. The removal of this negative feedback allows for increased functional Serotonin signaling across neural circuits associated with regulatory control, supporting the long-term modulation of Serotonin activity in the central nervous system.

As the pure S-enantiomer, Escitalopram avoids the R-enantiomer's distinct interaction profile. The R-enantiomer acts as a negative allosteric modulator, reducing the binding affinity at the SERT. By utilizing only the active S-form, Ciral provides high SERT blockade affinity and a targeted modulation of the Serotonergic pathway, avoiding modulation of other transporter systems.

Dosage and Administration Information

Ciral (Escitalopram) is administered orally once per day, taken as either a tablet or an oral solution, which may be consumed with or without food. The following information describes the administration protocol.

Administration Scope Detail
Route of administration Oral (by mouth) only.
Dosing schedule Standard Start: 10 mg once daily. Maximum Dose: 20 mg per day.
Timing in relation to meals Can be taken with or without food.
Age-group administration rules Older Adults/Hepatic Impairment: Maximum recommended daily dose is 10 mg.
Special procedural conditions Upon discontinuation, the dose must be gradually tapered over time.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral.
Frequency pattern Once daily (QD).
Use-context constraints Defined by specific dose limits for geriatric and hepatic populations.

Resulting Procedural Structure

Step Sequence:

  • Daily Dose: The required amount is taken by mouth once per day, which can be in the morning or evening.
  • Dose Flexibility: The daily dose can be adjusted between 10 mg and the 20 mg maximum (10 mg for specific populations).
  • Long-Term Pattern: The medication is generally used for continuous maintenance, with duration determined by the clinical scenario.
  • Cessation Protocol: The dose must be reduced gradually over a set period before complete cessation.

Connection to the Overall Use Protocol

The use protocol for Ciral involves a precise, once-daily oral administration, with the maximum dosage capped at 20 mg per day for most adults and a strict 10 mg limit for elderly and hepatically impaired individuals. These parameters describe the method for the initiation, maintenance, and concluding of the drug's administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Ciral

Research on Ciral was primarily evaluated in short-term Randomized Controlled Trials (RCTs) to examine its use in Major Depressive Disorder (MDD). These studies were designed to compare Ciral to an inactive pill (placebo). Researchers monitored changes in symptom intensity over defined time intervals, using specialized clinical rating scales like the MADRS and HAM-D. Studies explored symptom change and outcomes reflecting daily functioning in adult and certain adolescent populations. Long-term maintenance studies were designed to explore Ciral's role in monitoring participants over periods up to a year or more, focusing on the prevention of symptom recurrence. Limited information for long-term outcomes is available, and data for highly treatment-resistant groups remain insufficient.

Ciral was evaluated in short-term research focusing on Generalized Anxiety Disorder (GAD). These studies primarily involved adult outpatients and used RCT designs to examine outcomes monitored during periods of increased symptom activity, measured using standardized tools like the HAMA scale. Research examined measurements recorded during the study period when comparing the Ciral group to the placebo group. Follow-up durations were often short, and the systematic study of relapse prevention beyond the acute phase has not been as extensively characterized as the evidence for MDD.

Research was also studied for use in conditions such as Social Anxiety Disorder and Panic Disorder. Studies explored short-term symptom changes in these areas, reporting findings describing group patterns over observation periods of eight to twelve weeks. The volume of dedicated research for these conditions is smaller than for MDD and GAD. In the younger population, Ciral was evaluated in studies involving adolescents (12-17 years old). Research exploring short-term symptom changes in this group reported mixed findings, and data for children below the age of 12 is lacking. The overall research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. NICE Guideline: Depression in Adults: Recognition and Management

Frequently Asked Questions (FAQ)

Common questions about Ciral (FAQ)


Q: How quickly should someone expect Ciral to start working?

A: While Ciral’s action at the molecular level begins with the first administration, the full benefit generally takes longer to develop. Official studies indicate that the full benefit relies on a slower process of adaptation within the nervous system, often requiring several weeks of continuous, consistent use before noticeable changes are observed. Steady-state drug levels are typically achieved within 7 to 10 days.


Q: Does Ciral interact with common over-the-counter pain relievers?

A: Regulatory documents advise that taking Ciral along with nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin or ibuprofen, may increase the potential for abnormal bleeding. Both Ciral and NSAIDs can interfere with the processes that help blood clot, and is a factor documented in the official regulatory information.


Q: What kind of research has been done on Ciral's long-term use?

A: Research on Ciral includes specific long-term maintenance studies. These trials were designed to examine the drug's effectiveness and role over extended periods, with some observation lasting for a year or more. Regulatory information indicates that the long-term usefulness is generally subject to periodic reassessment.


Q: Can Ciral be taken during pregnancy or breastfeeding?

A: Official labeling states that Ciral should only be used during pregnancy if the potential benefit is judged to outweigh the potential risk to the developing fetus. For breastfeeding mothers, caution is advised. Decisions about use during these times are reserved for professional judgment concerning the individual risk/benefit profile.


Q: What should I do if I miss a dose of Ciral?

A: Official patient information states that a dose may be taken as soon as it is remembered. However, if it is very close to the time of your next scheduled dose, the dose is typically skipped. It is officially advised not to take a double dose to make up for a single missed dose.


Q: What happens if you accidentally take two Ciral pills?

A: The official product information contains details about accidental overdosage, which reports specific human experiences. In such cases, there is no specific treatment to reverse the effects, and medical monitoring is advised. Contacting a medical professional is advised in instances where more than the prescribed amount is taken.


Q: Can Ciral affect my ability to drive or operate machinery?

A: Ciral is documented to have the potential to interfere with cognitive and motor performance due to documented side effects like fatigue and somnolence (drowsiness). The official label includes a cautionary statement that use may require caution when operating hazardous machinery, such as driving a motor vehicle.


Q: Is Ciral the same type of medicine as [similar generic drug name]?

A: Ciral is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). This class includes many different prescription medicines that share a similar mechanism of action: they block the reuptake of serotonin. While they belong to the same pharmacological class, each specific SSRI has a distinct chemical structure and profile.


Q: Do people typically take Ciral for a long time, or is it short-term?

A: Ciral is officially indicated for the acute (initial) treatment of certain conditions and may also be prescribed for maintenance treatment. Maintenance treatment involves taking the medicine continuously over a longer period. Regulatory information indicates that the long-term usefulness of the medicine is subject to periodic reassessment.


Q: Is it common to feel tired when first starting Ciral?

A: Yes, Fatigue and Somnolence (drowsiness) are listed as common adverse reactions documented in clinical trials for Ciral. These effects were often reported when patients first started taking the medicine.


Q: Can I stop taking Ciral suddenly if I feel better?

A: No, official documentation strongly recommends that Ciral should not be stopped abruptly. The official label mandates that upon discontinuation, the dose must be gradually reduced or tapered over a period of time to help prevent possible discontinuation symptoms.


Q: Why do some people say Ciral caused weight changes for them?

A: Official labeling documents that changes in appetite, including decreased appetite and weight loss, have been reported in clinical trials for certain populations, such as adolescents. Although generally considered to have a minimal effect on weight in adults, official information documents that changes in weight are subject to monitoring.


Q: Is there a generic version of Ciral available?

A: Yes, Ciral's active ingredient, Escitalopram, is available in generic versions. Regulatory agencies confirm that generic forms are required to be equivalent to the brand-name product in terms of quality, strength, dosage, and effectiveness.


Q: Does Ciral interact with alcohol?

A: While clinical trials did not show Ciral increasing alcohol's effects on motor or mental skills, official product information contains a cautionary statement against the use of alcohol while taking the medicine. This is a common precaution with psychoactive medications.


Q: Are there any reported interactions between Ciral and herbal supplements?

A: Official regulatory warnings advise against combining Ciral with other medicines or supplements that affect serotonin levels. Specifically, the herbal remedy St. John’s wort is mentioned, as its co-use is not advised due to the potential for increased risk of adverse reactions, such as Serotonin Syndrome.


Q: How long does Ciral stay in your system after stopping it?

A: The active substance in Ciral, Escitalopram, has an average elimination half-life of approximately 27 to 32 hours in most adults. This half-life is a measure of the time required for half of the drug to be cleared from the body.


Q: Is Ciral often confused with another medication?

A: Ciral (Escitalopram) is the active single-isomer of the related medication, Citalopram. For safety, the official label explicitly prohibits use in patients known to be hypersensitive to either escitalopram or citalopram, indicating a recognized connection between the two compounds.


Q: Can Ciral be taken if someone is also taking medication for blood pressure?

A: Official documents note that a serious adverse reaction called Serotonin Syndrome can involve autonomic instability, including unstable blood pressure. Regulatory documents indicate that patients using blood pressure medication may be subject to closer clinical observation due to the potential for complex drug interactions involving metabolism.

How should Ciral be stored and disposed of?

The storage and disposal of Ciral (Escitalopram Oxalate) must strictly follow the official instructions documented by health authorities to ensure product stability and safety.

Storage Requirements

Condition Details (Official Labeling)
Temperature Store at 25°C (77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F), consistent with Controlled Room Temperature.
Protection The oral solution bottle must be kept closed tightly. Tablets should remain in their original package to protect from moisture.
Child Safety Keep Ciral and all medicines out of the sight and reach of children.

Disposal Instructions

Any unused product or waste material must be disposed of in accordance with local requirements. The medication should not be released into the environment or public waterways. Patients should utilize drug take-back programs or follow specific household trash disposal guidelines for unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ciral found in:

A-Z Index: